A prospective multicenter cohort study across 31 hospitals in China reported that a novel antimicrobial regimen improved treatment success and reduced failure in patients with retreated drug-sensitive pulmonary tuberculosis. Investigators reported no increase in adverse events, supporting the regimen as a potential operational step-up for previously treated populations.